Lately most of the conversations I have with patients about semaglutide do not start with pharmacology or mechanism of action. They start with cost. Almost every time.
Wegovy is expensive. In many cases it is well over a thousand dollars per month without insurance coverage, and in some situations even higher depending on pharmacy pricing, region, and insurance negotiations that often do not favor the patient. Ozempic sits in a similar range when it is being used off label for weight loss rather than diabetes.
Compounded semaglutide, during the period when it was widely available, was often somewhere between a couple hundred dollars and maybe three hundred or four hundred dollars per month. Sometimes less depending on the provider. That difference is not a minor detail in clinical practice. It is often the difference between starting treatment or not starting at all.
So it became very common for patients to come in already having looked into it. Sometimes they had already signed up through telehealth platforms. Sometimes they had already received a prescription and were just telling me afterward. And in many cases the decision had already been made before we ever got into the actual medical discussion.
From a purely human standpoint I understood that completely. From a systems standpoint it also made sense. From a safety and pharmacology standpoint it is where things start to get more complicated and less straightforward.
A lot of patients were told something like it is basically the same medication just made somewhere else. That statement sounds simple and reassuring. And in a very broad sense it is trying to describe something real. But it leaves out a lot of important details that matter when you are actually using these medications at scale.
What compounding actually means in real clinical practice
Compounding pharmacies are not unusual in medicine. They are a standard part of the healthcare system and have been for a long time. They are not experimental or fringe operations when used appropriately.
We rely on them for a number of legitimate reasons. Sometimes a patient needs a dose that is not commercially available. Sometimes a child requires a formulation that does not exist in a standard product. Sometimes a patient has an allergy to a dye or preservative that is present in manufactured medications. Sometimes a drug is discontinued and there is still a clinical need for it.
In those situations compounding is not just helpful. It is often the only way to deliver appropriate care.
There is also a legal structure that allows compounding under certain conditions. One of the most important is a declared drug shortage. When the FDA determines that a medication is in shortage, certain compounding pharmacies and outsourcing facilities are permitted to produce versions of that medication to help meet demand.
That is the context in which compounded semaglutide expanded.
Semaglutide was placed on the FDA shortage list in 2022. That was during a period of rapidly increasing demand for GLP 1 medications, both for diabetes and weight management. Supply simply did not keep up. That shortage designation remained in place through 2024.
During that time compounding activity increased significantly. Telehealth companies built entire systems around prescribing and dispensing compounded semaglutide. Pharmacies scaled up production. Prescribing became extremely streamlined. From the patient side access improved almost overnight compared to traditional healthcare pathways.
For many patients it did not feel like an alternative option. It felt like the only option that was realistically available.
Then in early 2025 semaglutide came off the shortage list. That change did not receive a huge amount of public attention outside of medical and regulatory spaces, but it had major implications. It effectively removed the legal justification for routine large scale compounding in most standard pharmacy settings.
Some outsourcing facilities were allowed a short transition period. State licensed compounding pharmacies largely had to stop preparing semaglutide. And what remained became much more fragmented, less standardized, and less clearly regulated.
The chemical form issue that was largely missed in public discussion
One of the more technically important issues that did not get enough attention during the widespread use of compounded semaglutide is the actual molecular form being used.
The semaglutide in Wegovy and Ozempic is a specific base molecule. It has been studied extensively in large clinical trials. We understand how it behaves in the body in a fairly detailed way. That includes absorption, half life, receptor binding, and dose response across populations.
That type of data is what allows us to build predictable dosing schedules and expected outcomes.
Many compounded versions did not use that exact base form. Instead they used semaglutide salts such as semaglutide sodium or semaglutide acetate. These forms can be easier to handle in a compounding environment and in some cases may be more stable in certain preparations.
That is part of why they became common.
The issue is not that these forms are obviously unsafe or toxic. The issue is that they are not identical to the approved formulation, and we do not have strong high quality clinical data demonstrating that they behave the same way at the doses used for weight management.
That difference matters in pharmacology. Even small differences in molecular form can change absorption characteristics or bioavailability or how long a drug remains active in the body.
During the shortage period dosing protocols often treated these forms as interchangeable. In many cases that assumption was built directly into prescribing workflows.
Sometimes patients had expected results. Sometimes they did not. And sometimes the response was inconsistent in ways that were difficult to interpret clinically.
The problem is that we cannot always go back and clearly separate which outcomes were due to formulation differences and which were due to other factors.
That uncertainty is one of the central issues with compounded semaglutide use at scale.
Variability between pharmacies and what patients actually received
Another major factor that often gets overlooked is how much variability existed between compounding pharmacies themselves.
Unlike commercial pharmaceutical manufacturing, which is highly standardized and tightly regulated at scale, compounding practices can vary significantly depending on the facility.
With semaglutide this became very visible.
Some compounded products included vitamin B12. The reasoning was usually related to energy levels, fatigue reduction, or general tolerability. Other formulations included compounds such as glutathione or other additives that were not part of any original semaglutide clinical trial design.
Individually these substances are not necessarily problematic. Vitamin B12 is widely used in medicine. Glutathione is also used in certain contexts. The concern is not individual toxicity in isolation. The concern is lack of controlled data on how these combinations behave when used long term alongside semaglutide in large populations.
Once you introduce additional variables into a metabolic medication that is already acting on appetite regulation, gastrointestinal function, and glucose control, interpretation becomes more difficult.
There were also significant practical differences in how medications were prepared and dispensed.
Some patients received prefilled syringes. Others received vials and had to draw up doses manually. Some instructions used milligrams while others used units, requiring conversion that was not always clearly explained. Concentrations could differ depending on pharmacy source.
In real world practice this creates opportunities for dosing inconsistencies. And those inconsistencies did occur. Not because patients were careless, but because the system required precision without always providing standardized tools.
During the period of peak use there were adverse event reports submitted through regulatory systems including FDA MedWatch. Some of these involved significant clinical concerns. It is important to say that reporting does not automatically mean causation is established. But it does indicate that real world outcomes were not always uniform.
In many cases it is extremely difficult to determine the exact cause of a given adverse event. Dose variability, formulation differences, contamination risk, storage conditions, and user handling can all overlap.
That ambiguity is part of the safety concern.
Why patients still chose compounded semaglutide
Despite all of these complexities the reason patients used compounded semaglutide is actually very straightforward when you look at it from a practical standpoint.
It was cost and access.
If one medication is over a thousand dollars per month and another is a few hundred dollars per month, that difference is not marginal. It is decisive. For many patients insurance coverage was not available or required prior authorizations that delayed or prevented access entirely.
In that environment compounded semaglutide became the only realistic path to treatment.
Telehealth platforms made access even easier. Patients could be evaluated quickly and prescriptions could be issued without the traditional barriers of in person visits, insurance approval, or specialist referral.
For many people who had already been told no elsewhere in the healthcare system it felt like finally having an option that was actually reachable.
From a clinical perspective I do not interpret that as irrational behavior. I interpret it as patients responding to the constraints of the system they were operating within.
What we saw clinically in terms of outcomes
Looking back at patient outcomes there was a wide range of responses to compounded semaglutide.
Some patients experienced weight loss that looked very similar to what we would expect from FDA approved semaglutide products. Appetite suppression was consistent and gradual dose escalation was tolerated.
Other patients had more inconsistent responses where weight loss did not track with dose in a predictable way. Some reported fluctuations that were harder to explain clinically.
There were also patients who experienced side effects that did not match typical semaglutide patterns in a straightforward way. That included gastrointestinal symptoms that were either more variable or less predictable than what we usually see with standardized formulations.
In hindsight that variability makes more sense given the differences in formulation, dosing instructions, and preparation methods.
The challenge for clinicians is that we rely heavily on predictability when prescribing medications. When a drug is standardized we can anticipate response patterns and adjust dosing in a controlled way. Compounded medications introduce variability that makes that process less reliable.
Where things stand now clinically
At this point in time, with the shortage period officially over, the general clinical direction is to transition patients who are continuing therapy onto FDA approved semaglutide products when possible.
This is not about judging past use. It is about aligning treatment with products that have consistent formulation and well established clinical data.
Wegovy is currently the primary FDA approved semaglutide medication for weight management. It is administered as a once weekly injection with standardized dosing and delivery devices. There is also oral Wegovy, a daily tablet option for patients who prefer not to inject, using the same active molecule with its own established dosing protocol. Ozempic contains the same active ingredient but is approved for type 2 diabetes and is sometimes used off label in weight management settings depending on clinical judgment.
The key difference compared to compounded versions is consistency. Every dose is identical. Every pen is manufactured under strict quality controls. And most importantly the clinical trial data corresponds directly to the product being used in practice.
That alignment between evidence and real world use is something that becomes easy to take for granted until it is no longer guaranteed.
The cost problem remains unresolved
One important point that cannot be ignored is that removing compounded semaglutide did not resolve the underlying issue of affordability.
It simply removed a lower cost access point.
There are manufacturer assistance programs and some insurance changes that have improved access for certain patients, but many people still face significant financial barriers to treatment.
So the access problem has not gone away. It has just shifted back toward the insurance and pricing structure of branded pharmaceuticals.
Final perspective
Compounded semaglutide filled a real and important gap during a period when demand exceeded supply and patients needed alternatives to remain on therapy.
At the same time it introduced variability in formulation, dosing, and chemical equivalence that was not always fully appreciated at the time.
Most patients were not making unsafe or careless decisions. They were making practical decisions based on cost, access, and availability.
Now that the shortage period has ended, the focus in clinical practice shifts back toward standardized medications where dosing is consistent, formulations are well defined, and outcomes are supported by large scale clinical data that directly matches the product being used.
